Contact
Please use this form to send email to PR contact of this press release:
Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma
TO:
Please use this form to send email to PR contact of this press release:
Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma
TO: